Viridian Therapeutics price target lowered to $22 from $34 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Viridian Therapeutics (VRDN) to $22 from $34 and keeps a Buy rating on the shares. While the REVEAL-1 establishes elegrobart as active in thyroid eye disease, the dataset fell short of demonstrating IV-like efficacy, with a mixed profile across endpoints and between dosing regimens, the analyst tells investors in a research note. The firm reduced peak sales expectations for elegrobart as a result.